MS & Neuroimmunology Clinics, Concord Repatriation General Hospital, University of Sydney, NSW, Sydney, Australia.
MS & Neuroimmunology Clinics, Concord Repatriation General Hospital, University of Sydney, NSW, Sydney, Australia; Brain & Mind Centre, University of Sydney, NSW, Sydney, Australia.
J Neuroimmunol. 2024 Apr 15;389:578330. doi: 10.1016/j.jneuroim.2024.578330. Epub 2024 Mar 14.
Siponimod is a sphingosine 1-phosphate receptor (S1P) modulator used to treat secondary progressive multiple sclerosis (SPMS). We report 3 SPMS patients treated with siponimod who developed new or worsening peripheral oedema soon after commencing treatment. In one case, peripheral oedema resulted in immobility. Siponimod-related peripheral oedema deserves wider recognition due to the potential for morbidity and over-investigation. Clinicians should assess for pre-existing oedema and coexisting conditions that may predispose to developing peripheral oedema prior to commencing siponimod.
西尼莫德是一种鞘氨醇 1-磷酸受体（S1P）调节剂，用于治疗继发进展型多发性硬化症（SPMS）。我们报告了 3 例接受西尼莫德治疗的 SPMS 患者，他们在开始治疗后不久出现新的或恶化的外周水肿。在一个病例中，外周水肿导致患者无法活动。鉴于潜在的发病率和过度检查，西尼莫德相关的外周水肿值得更广泛的认识。在开始使用西尼莫德之前，临床医生应评估是否存在可能导致外周水肿的先前存在的水肿和并存疾病。
